Sartans` effects of chronic heart failure in a family doctor practice (literature review)

##plugins.themes.bootstrap3.article.sidebar##

PDF (Українська)
Published: May 20, 2016
DOI: https://doi.org/10.30841/2307-5112.2(64).2016.102620
Keywords:
sartans, chronic heart failure, pleyotropic effects,

##plugins.themes.bootstrap3.article.main##

Н. В. Деміхова
Сумський державний університет, Ukraine

Abstract

Sartans are the essential drugs in the treatment of socially significant diseases such as hypertension, chronic heart failure, diabetes. Their effects are determined not only antihypertensive effect, they have nor1 malization renin1angiotensin1aldosterone system in general, and nephroprotektion, neurocytoprotection, metabolic effect and effect on connective tissue.

##plugins.themes.bootstrap3.article.details##

How to Cite
Деміхова, Н. В. (2016). Sartans` effects of chronic heart failure in a family doctor practice (literature review). Family Medicine, (2(64), 157–159. https://doi.org/10.30841/2307-5112.2(64).2016.102620
Issue
No. 2(64) (2016)
Section
Lectures and reviews
Copyright (c) 2020 Н. В. Деміхова

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biography

Н. В. Деміхова, Сумський державний університет

N.V. Demikhova

References

Беленков Ю.Н. Лечение сердечной недостаточности в XXI веке: достижения, вопросы и уроки доказательной медицины / Ю.Н. Беленков, В.Ю. Мареев // Кардиология. – 2008. – № 2. – С. 6–16.

Беленков Ю.Н. Хроническая сердечная недостаточность. Избранные лекции по кардиологии / Ю.Н. Беленков, В.Ю. Мареев, Ф.Т. Агеев. – М. : ГЭОТАР&Медиа, 2006. – 432 с.

Белоусов Ю.Б. Перспективные направления в лечении сердечной недостаточности / Ю.Б. Белоусов, А.А. Упницкий, Н.Ю. Ханина // Качественная клиническая практика. – 2006. – № 1. – С. 2–9.

Гуревич М.А. Хроническая сердечная недостаточность: рук. для врачей / М.А. Гуревич. – М.: Практическая медицина, 2008. – 414 с.

Жиров И.В. Эналаприл и хроническая сердечная недостаточность: старый друг лучше новых двух? / И.В. Жиров, С.Н. Терещенко // Труд. пациент. – 2011. – Т. 9, № 1. – С. 6–10.

Мойсеєнко В.О. Патогенетичне обґрунтування використання лозартану у хворих на хронічну хворобу нирок з безсимптомною гіперурикемією / В.О. Мойсеєнко, О.В. Карпенко, Е.К. Красюк // Український журнал нефрології та діалізу. – 2012. – № 2 (34). – С. 48–52.

Нигматуллина Р.Р. Состояние симпатико-адреналовой системы у больных хронической сердечной недостаточностью / Р.Р. Нигматуллина [и др.] // Клиническая медицина. – 2009. – № 4. – С. 32–36.

Семеновых П.С. Нефропротекторные эффекты лористы (лосартана) у больных диабетической нефропатией / П.С. Семеновых, И.И. Топчий, В.Ю. Гальчинская // Артериальная гипертензия. – 2012. – № 5 (13). – С. 45–47.

Хроническая сердечная недостаточность / Ф.Т. Агеев, Г.П. Арутюнов, Ю.Н. Беленков и др. – М.: ГЭОТАР Медиа, 2010. – 336 с.

Barrios V. Candesartan in the treatment of hypertension: what have we learnt in the last decade? / V. Barrios, C. Escobar // Expert Opin. Drug Saf. – 2011. – Vol. 10, № 6. – P. 957–968.

Bernal J. Role of the reninangiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention / J. Bernal, S. Pitta, D. Thatai // Am. J. Cardiovasc. Drugs. – 2006. – Vol. 6, № 6. – P. 373–381.

Brenner B.M. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy? / B.M. Brenner, M.E. Cooper, D.De Zeeuw [et al.] // New Eng. J. Med. – 2001. – Vol. 345. – P. 861–869.

Casas J.P. Effect of inhibitors of the rennin&angiotensin system and other antihypertensive drugs on renal outcomes: systematic rewiew and metaanalysis / J.P. Casas, W. Chua, S. Loukogeorgakis et al. // Lancet. – 2005. – Dec. 10. – Vol. 366. – P. 2026–2033.

Cohen&Solal A. Diastolic heart failure / A. Cohen&Solal // Rev. Prat. – 2010. – Vol. 60, № 7. – P. 933–934.

Dahlof B. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in the hypertension study (LIFE): a randomized trial aganst atenolol / B. Dahlof, R.B. Devereux, S.E. Kjeldsen et al. // Lancet. – 2002. – Vol. 359. – P. 995–1003.

Ezekowitz J.A. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials / J.A. Ezekowitz, F.A. McAlister // Eur. Heart J. – 2009. – Vol. 30, № 4. – P. 469–477.

Ha J.W. Therapeutic strategies for diastolic dysfunction: a clinical perspective / J.W. Ha, J.K. Oh // J. Cardiovasc. Ultrasound. – 2009. – Vol. 17, № 3. – P. 86–95.

House A.A. Therapeutic strategies for heart failure in cardiorenal syndromes / A.A. House, M. Haapio, J. Lassus [et al.] / Am. J. Kidney. Dis. – 2010. – Vol. 56. – P. 759–773.

Isnard R. Pathophysiology of heart failure for clinicians / R. Isnard // Rev. Prat. – 2010. – Vol. 60, № 7. – P. 916–920.

Janardhanan R. Therapeutic approaches to diastolic dysfunction / R. Janardhanan, A.S. Desai, S.D. Solomon // Curr. Hypertens. Rep. – 2009. – Vol. 11, № 4. – P. 283–291.

Kunz R. Meta&analysis: effect of monotherapy and combination therapy with inhibitors of the rennin-angiotensin system on proteinuria in renal disease / R. Kunz, C. Friedrich, M. Wolbers, J.F.E. Mann // Ann. Intern. Med. – 2008. – Vol. 148. – P. 30–48.

Lewis E.J. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes / E.J. Lewis, L.G. Hunsicker, W.R. Clarke [et al.] // New Eng. J. Med. – 2001. – № 145. – P. 851–860.

Massie B.M. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction / B.M. Massie, P.E. Carson, J.J. McMurray // New Engl. J. Med. – 2008. – Vol. 359. – P. 2456–2467.

Matchar D.B. Systemetic rewiew: comparative effectiveness of ACE inhibitors and angiotensin II receptor blockers tor treating essential hypertension / D.B. Matchar, D.C. McCrory, L.A. Orlando [et al.] // Ann. Intern. Med. – 2008. – Vol. 148. – P. 16–29.

McAlister F.A. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials / F.A. McAlister [et al.] // Eur. Heart J. – 2012. – Vol. 33, № 4. – P. 505–514.

Metra M. Treatment of heart failure in the elderly: never say it’s too late / M. Metra, L. Cas, B. Massie // European Heart Journal. – 2009. – Vol. 30. – P. 391–393.

Ruilope L.M. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence / L.M. Riulope, J. Segura // Clin. Ther. – 2003. – Vol. 25, № 12. – P. 3044–3064.

Sciarretta S. Role of the reninangiotensin&aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction / S. Sciarretta [et al.] // Clin. Sci (Lond). – 2009. – Vol. 116, № 6. – P. 467–477.

Takahashi S. Effects of combination treatment using anti&hyperuricaemic agents with fenofibrate and/or losartane on uric acid metabolism / S. Takahashi, Y. Moriwaki, T. Yamamoto [et al.] // Ann. Rheum. Dis. – 2003. – Vol. 62. – P. 572–575.

Taylor W. Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia / W. Taylor // Clin. Med. – 2002. – Vol. 80, № 2. – P. 77–78.

Zucker I.H. Neurohumoral stimulation / I.H. Zucker, K.P. Patel, H.D. Schultz // Heart Fail. Clin. – 2012. – Vol. 8, № 1. – P. 87–99.